2026 Q1 -tulosraportti
33 päivää sitten
‧1 t 1 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 66 | - | - | ||
| 49 436 | - | - | ||
| 54 112 | - | - | ||
| 2 797 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 839 287 | 839 287 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 839 287 | 839 287 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·3 t sittenWhy are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.
·1 t sitten10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/
·2.6.Doctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·2.6.Go to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.·2.6.It would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?- ·1.6.Today's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
- 1.6. · Muokattu1.6. · MuokattuJeg mener vi har nådd den februar-spåing som Borcherdinger gjorde om NY-godkjennelse veldig nært på. Så kan han jo ha spådd bittelitt feil. Men vi burde jo omtrentlig snart være i mål da? Får vi nådd nok en milepæle snart da? :) En eller annen dag vil jo New York-godkjenningen vel komme nokså sannsynlig. Og vi får en mellom-aktig boost i aksjekursen? Kan godkjenningen være priset inn allerede i dagens lave kurs? Jeg tviler litt. Det er vel vakuumet mellom neste nyhet vi føler på nå antar ihvertfall jeg. Finansiering er jo heller ikke endelig løst. Det vil vel være en betydelig aksjekursendring når finansiering som jo er et helt annet spørsmål, er løst på et eller annet vis. Så kommer det jo an på hvordan finansieringen blir løst.. Jeg spurte Gemini AI om hva som er hemskoen med New York godkjennelse for salg av PancreaSure i staten: "In the world of diagnostics, New York State approval is almost never a mere formality. While the final outcome will likely be positive, the process itself requires a meticulous "back-and-forth" where companies must actively feed the state specific pieces of data. Even though Immunovia cleared California’s strict Clinical Laboratory Evaluation Program (CLEP) guidelines and is approved in 49 states, New York’s Department of Health (NYSDOH) treats itself as a completely independent supreme regulatory body. They do not rubber-stamp any test based on another state's approval. The process involves specific data requirements and steps that explain why it takes time, along with the distinct pieces of information Immunovia must provide to satisfy New York. What New York Demands (The "Missing Pieces") When a company like Immunovia is "actively pursuing" New York approval, they are usually navigating a highly structured technical audit. The state requires a specialized, standalone application dossier that focuses heavily on three areas: Raw Validation Data: New York rarely accepts summarized clinical trial papers alone. Their reviewers typically demand the raw validation data from the clinical trials (such as the CLARITI study for PancreaSure). They want to re-verify how the test handles the 5-plex serum biomarkers (TIMP1, ICAM1, CTSD, TSP1, and CA 19-9) to ensure consistency. Standard Operating Procedures (SOPs) & QA: The NYSDOH evaluates the physical and digital workflow of the laboratory running the test. They require detailed documentation on how samples are shipped from New York clinics, how they are handled, and the exact software algorithms used to interpret the "positive" or "negative" cutoffs. The "Gating" Iteration: The approval process operates like a formal audit. New York reviews the submission, issues a list of highly technical questions or requests for clarification, and the company must submit amended protocols or extra data points. This cyclical nature is why it is rarely a quick administrative sign-off. Why Investors Can Rest Easy About the Outcome While it isn't a hands-off formality, it is highly likely a winnable process for Immunovia rather than a major roadblock. The California Indicator: California and New York have remarkably similar scientific standards for laboratory-developed tests (LDTs). Because Immunovia successfully cleared California’s rigorous hurdle, it proves that PancreaSure's clinical accuracy ($78.5\%$ sensitivity and $93.5\%$ specificity) and laboratory quality control are robust enough to withstand top-tier regulatory scrutiny. The company already has prestigious institutions inside New York, like NYU Langone/Perlmutter Cancer Center, implementing the test for patients via out-of-state framework arrangements. These centers understand the logistical gaps of traditional surveillance (like MRIs or endoscopic ultrasounds) and want local access. The Bottom Line It is a procedural hurdle, not a scientific doubt. Immunovia doesn't need to go back to the drawing board to invent new data or run new trials; they simply need to satisfy New York's administrative requirements by feeding them the exact quality-control documentation and raw data formatting they demand.
- ·22.5.When will the parties succeed in coming to an agreement, with a partnership for PancreaSure?3 ääntä PäättynytLiity Nordnet Socialiin nähdäksesi tuloksetsummer 202633%Sept - Nov 2026 sometime0%2027 sometime33%later33%
·5.6.The stock can quickly rise (unnaturally and without news) if it gets some attention on various forums (not Nordnet) - but then I'm also out!·3 päivää sittenNo impossibility, but no one knows exactly when. There are probably various places where people meet to build optimism and pessimism that many don't read. But which can have some significance. The question is just whether it gains enough weight to move the price much, when it first happens. I am not a reader of such things as of now. See that some mention places like Discord and such, and ask for links. If one were completely trading-focused, one should probably have followed many such places. I don't even have a Discord account myself, so I haven't bothered. Remember that the Gamestop boosting happened on alternative forums
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
33 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenWhy are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.·1 t sitten10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/
- ·2.6.Doctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·2.6.Go to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.·2.6.It would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?
- ·1.6.Today's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
- 1.6. · Muokattu1.6. · MuokattuJeg mener vi har nådd den februar-spåing som Borcherdinger gjorde om NY-godkjennelse veldig nært på. Så kan han jo ha spådd bittelitt feil. Men vi burde jo omtrentlig snart være i mål da? Får vi nådd nok en milepæle snart da? :) En eller annen dag vil jo New York-godkjenningen vel komme nokså sannsynlig. Og vi får en mellom-aktig boost i aksjekursen? Kan godkjenningen være priset inn allerede i dagens lave kurs? Jeg tviler litt. Det er vel vakuumet mellom neste nyhet vi føler på nå antar ihvertfall jeg. Finansiering er jo heller ikke endelig løst. Det vil vel være en betydelig aksjekursendring når finansiering som jo er et helt annet spørsmål, er løst på et eller annet vis. Så kommer det jo an på hvordan finansieringen blir løst.. Jeg spurte Gemini AI om hva som er hemskoen med New York godkjennelse for salg av PancreaSure i staten: "In the world of diagnostics, New York State approval is almost never a mere formality. While the final outcome will likely be positive, the process itself requires a meticulous "back-and-forth" where companies must actively feed the state specific pieces of data. Even though Immunovia cleared California’s strict Clinical Laboratory Evaluation Program (CLEP) guidelines and is approved in 49 states, New York’s Department of Health (NYSDOH) treats itself as a completely independent supreme regulatory body. They do not rubber-stamp any test based on another state's approval. The process involves specific data requirements and steps that explain why it takes time, along with the distinct pieces of information Immunovia must provide to satisfy New York. What New York Demands (The "Missing Pieces") When a company like Immunovia is "actively pursuing" New York approval, they are usually navigating a highly structured technical audit. The state requires a specialized, standalone application dossier that focuses heavily on three areas: Raw Validation Data: New York rarely accepts summarized clinical trial papers alone. Their reviewers typically demand the raw validation data from the clinical trials (such as the CLARITI study for PancreaSure). They want to re-verify how the test handles the 5-plex serum biomarkers (TIMP1, ICAM1, CTSD, TSP1, and CA 19-9) to ensure consistency. Standard Operating Procedures (SOPs) & QA: The NYSDOH evaluates the physical and digital workflow of the laboratory running the test. They require detailed documentation on how samples are shipped from New York clinics, how they are handled, and the exact software algorithms used to interpret the "positive" or "negative" cutoffs. The "Gating" Iteration: The approval process operates like a formal audit. New York reviews the submission, issues a list of highly technical questions or requests for clarification, and the company must submit amended protocols or extra data points. This cyclical nature is why it is rarely a quick administrative sign-off. Why Investors Can Rest Easy About the Outcome While it isn't a hands-off formality, it is highly likely a winnable process for Immunovia rather than a major roadblock. The California Indicator: California and New York have remarkably similar scientific standards for laboratory-developed tests (LDTs). Because Immunovia successfully cleared California’s rigorous hurdle, it proves that PancreaSure's clinical accuracy ($78.5\%$ sensitivity and $93.5\%$ specificity) and laboratory quality control are robust enough to withstand top-tier regulatory scrutiny. The company already has prestigious institutions inside New York, like NYU Langone/Perlmutter Cancer Center, implementing the test for patients via out-of-state framework arrangements. These centers understand the logistical gaps of traditional surveillance (like MRIs or endoscopic ultrasounds) and want local access. The Bottom Line It is a procedural hurdle, not a scientific doubt. Immunovia doesn't need to go back to the drawing board to invent new data or run new trials; they simply need to satisfy New York's administrative requirements by feeding them the exact quality-control documentation and raw data formatting they demand.
- ·22.5.When will the parties succeed in coming to an agreement, with a partnership for PancreaSure?3 ääntä PäättynytLiity Nordnet Socialiin nähdäksesi tuloksetsummer 202633%Sept - Nov 2026 sometime0%2027 sometime33%later33%·5.6.The stock can quickly rise (unnaturally and without news) if it gets some attention on various forums (not Nordnet) - but then I'm also out!·3 päivää sittenNo impossibility, but no one knows exactly when. There are probably various places where people meet to build optimism and pessimism that many don't read. But which can have some significance. The question is just whether it gains enough weight to move the price much, when it first happens. I am not a reader of such things as of now. See that some mention places like Discord and such, and ask for links. If one were completely trading-focused, one should probably have followed many such places. I don't even have a Discord account myself, so I haven't bothered. Remember that the Gamestop boosting happened on alternative forums
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 66 | - | - | ||
| 49 436 | - | - | ||
| 54 112 | - | - | ||
| 2 797 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 839 287 | 839 287 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 839 287 | 839 287 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
33 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenWhy are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.·1 t sitten10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/
- ·2.6.Doctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·2.6.Go to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.·2.6.It would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?
- ·1.6.Today's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
- 1.6. · Muokattu1.6. · MuokattuJeg mener vi har nådd den februar-spåing som Borcherdinger gjorde om NY-godkjennelse veldig nært på. Så kan han jo ha spådd bittelitt feil. Men vi burde jo omtrentlig snart være i mål da? Får vi nådd nok en milepæle snart da? :) En eller annen dag vil jo New York-godkjenningen vel komme nokså sannsynlig. Og vi får en mellom-aktig boost i aksjekursen? Kan godkjenningen være priset inn allerede i dagens lave kurs? Jeg tviler litt. Det er vel vakuumet mellom neste nyhet vi føler på nå antar ihvertfall jeg. Finansiering er jo heller ikke endelig løst. Det vil vel være en betydelig aksjekursendring når finansiering som jo er et helt annet spørsmål, er løst på et eller annet vis. Så kommer det jo an på hvordan finansieringen blir løst.. Jeg spurte Gemini AI om hva som er hemskoen med New York godkjennelse for salg av PancreaSure i staten: "In the world of diagnostics, New York State approval is almost never a mere formality. While the final outcome will likely be positive, the process itself requires a meticulous "back-and-forth" where companies must actively feed the state specific pieces of data. Even though Immunovia cleared California’s strict Clinical Laboratory Evaluation Program (CLEP) guidelines and is approved in 49 states, New York’s Department of Health (NYSDOH) treats itself as a completely independent supreme regulatory body. They do not rubber-stamp any test based on another state's approval. The process involves specific data requirements and steps that explain why it takes time, along with the distinct pieces of information Immunovia must provide to satisfy New York. What New York Demands (The "Missing Pieces") When a company like Immunovia is "actively pursuing" New York approval, they are usually navigating a highly structured technical audit. The state requires a specialized, standalone application dossier that focuses heavily on three areas: Raw Validation Data: New York rarely accepts summarized clinical trial papers alone. Their reviewers typically demand the raw validation data from the clinical trials (such as the CLARITI study for PancreaSure). They want to re-verify how the test handles the 5-plex serum biomarkers (TIMP1, ICAM1, CTSD, TSP1, and CA 19-9) to ensure consistency. Standard Operating Procedures (SOPs) & QA: The NYSDOH evaluates the physical and digital workflow of the laboratory running the test. They require detailed documentation on how samples are shipped from New York clinics, how they are handled, and the exact software algorithms used to interpret the "positive" or "negative" cutoffs. The "Gating" Iteration: The approval process operates like a formal audit. New York reviews the submission, issues a list of highly technical questions or requests for clarification, and the company must submit amended protocols or extra data points. This cyclical nature is why it is rarely a quick administrative sign-off. Why Investors Can Rest Easy About the Outcome While it isn't a hands-off formality, it is highly likely a winnable process for Immunovia rather than a major roadblock. The California Indicator: California and New York have remarkably similar scientific standards for laboratory-developed tests (LDTs). Because Immunovia successfully cleared California’s rigorous hurdle, it proves that PancreaSure's clinical accuracy ($78.5\%$ sensitivity and $93.5\%$ specificity) and laboratory quality control are robust enough to withstand top-tier regulatory scrutiny. The company already has prestigious institutions inside New York, like NYU Langone/Perlmutter Cancer Center, implementing the test for patients via out-of-state framework arrangements. These centers understand the logistical gaps of traditional surveillance (like MRIs or endoscopic ultrasounds) and want local access. The Bottom Line It is a procedural hurdle, not a scientific doubt. Immunovia doesn't need to go back to the drawing board to invent new data or run new trials; they simply need to satisfy New York's administrative requirements by feeding them the exact quality-control documentation and raw data formatting they demand.
- ·22.5.When will the parties succeed in coming to an agreement, with a partnership for PancreaSure?3 ääntä PäättynytLiity Nordnet Socialiin nähdäksesi tuloksetsummer 202633%Sept - Nov 2026 sometime0%2027 sometime33%later33%·5.6.The stock can quickly rise (unnaturally and without news) if it gets some attention on various forums (not Nordnet) - but then I'm also out!·3 päivää sittenNo impossibility, but no one knows exactly when. There are probably various places where people meet to build optimism and pessimism that many don't read. But which can have some significance. The question is just whether it gains enough weight to move the price much, when it first happens. I am not a reader of such things as of now. See that some mention places like Discord and such, and ask for links. If one were completely trading-focused, one should probably have followed many such places. I don't even have a Discord account myself, so I haven't bothered. Remember that the Gamestop boosting happened on alternative forums
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 66 | - | - | ||
| 49 436 | - | - | ||
| 54 112 | - | - | ||
| 2 797 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 839 287 | 839 287 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 839 287 | 839 287 | 0 | 0 |